Category I Code Approved for Two-Level Cervical Arthroplasty

The LDR Mobi-C(R) Cervical Disc is FDA Approved for Two-Level Cervical Arthroplasty


AUSTIN, Texas, March 11, 2014 (GLOBE NEWSWIRE) -- LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced today that the Current Procedural Terminology (CPT) Editorial Panel has accepted the addition of Category I code 22858X as an add-on code to support two-level cervical arthroplasty procedures. The coding change was recently disclosed on the American Medical Association (AMA) website and will become effective on January 1, 2015. Concurrent with this addition will be the elimination of the Category III code 0092T.

"This coding change is a significant milestone in the field of cervical disc replacement. While two-level arthroplasty procedures are being performed today, beginning in 2015, they will have the full coding and payment structure necessary to provide patients access to this very important procedure," said Christophe Lavigne, President and CEO of LDR. "We are very pleased that the North American Spine Society supported the application consistent with their efforts in advocating for evidence-based medicine and fair coding and reimbursement decisions. We feel that this is another important step in the process to provide broad availability to this beneficial treatment option to patients suffering from two-level cervical disc disease."

About Mobi-C

Mobi-C is a cobalt chromium alloy and polyethylene, mobile-bearing prosthesis specifically designed as a bone-sparing, cervical intervertebral disc replacement for both one and two-level indications. In addition to the unique mobile-bearing feature, Mobi-C offers a simplified surgical technique as compared to other, commercially available devices, all of which are approved by the U.S. Food and Drug Administration for one-level use only.

About LDR Holding

LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive VerteBRIDGE® fusion and Mobi® non-fusion technology platforms and are designed for applications in the lumbar and cervical spine. These technologies enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. LDR received approval from the FDA for the Mobi-C® cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR, visit www.ldr.com or www.cervicaldisc.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of LDR and members of its management team with respect to LDR's future business operations as well as the assumptions upon which such statements are based, including the potential impact of the new Category I code on LDR's business. Factors that could cause actual results to differ materially from those contemplated within this press release can also be found in LDR's Risk Factors disclosure in its Annual Report on Form 10-K, filed on March 4, 2014, and in LDR's other filings with the SEC. LDR disclaims any responsibility to update any forward-looking statements.



            

Tags


Contact Data